Piper Jaffray Gives Insight to Medical Technology Industry Overview
Piper Jaffray published a medical technology industry overview research report discussing bits and pieces from the 2012 Boston Atrial Fibrillation Symposium.
“Late last week, we attended the 17th annual Boston Atrial Fibrillation Symposium, a meeting of AF experts. Roughly 500 physicians attended, about the same as in 2011. We note that the treatment of AF continues to improve as technologies are advanced. Further, ablation technologies again dominated the forum. Product improvements from STJ, BSX, MDT, and ATRC were presented(…)Overall, we view AF treatment as an underpenetrated medical condition with above average growth potential. Atricure is the only pure-play AF stock in our coverage universe,” Piper Jaffray commented.
Piper Jaffray's current ratings are as follows: AtriCure Inc. (NASDAQ: ATRC), Neutral, $11.00 PT, closed Friday at $11.14. Boston Scientific Corporation (NYSE: BSX) Neutral, $6.00 PT, closed Friday at $5.52. Medtronic, Inc. (NYSE: MDT), Overweight, $40.00 PT, closed Friday at $38.65. St. Jude Medical, Inc. (NYSE: STJ), Overweight, $52.00 PT, closed Friday at $37.24.
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.